Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

[News]

Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.

More... (https://www.news-medical.net/news/20210127/Allarity-Therapeutics-announces-plans-to-test-antiviral-activity-of-stenoparib-drug.aspx)